Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aims: Nucleos(t)ide analogues (NA) withdrawal is an important cause of hepatitis B virus (HBV) infection relapse or flare, potentially triggering HBV-related acute-on-chronic liver failure (HBV-ACLF). Although both NA withdrawal and spontaneous severe acute exacerbation (SAE) of chronic hepatitis B are recognised HBV-ACLF triggers, comparative evidence regarding their distinct clinical trajectories remains absent. This multicenter retrospective cohort study sought to determine whether NA withdrawal independently predicts adverse outcomes in HBV-related ACLF compared to SAE-induced cases.
Methods: We retrospectively enrolled consecutive patients with HBV-ACLF admitted to four tertiary hospitals in China. The relationship between NA withdrawal and all-cause mortality in HBV-ACLF patients was evaluated using multivariate Cox regression analysis. Additionally, sensitivity analyses including propensity score matching (PSM) and inverse probability treatment weighting (IPTW) were performed.
Results: Among the 313 HBV-ACLF patients, 66 patients (21.1%) experienced NA withdrawal. HBV-ACLF patients in the NA-withdrawal group exhibited lower liver enzyme levels and higher infection rates at diagnosis compared with those in the NA-naïve group. Multivariate Cox regression models indicated that, after adjusting for demographic and clinical confounders, NA withdrawal was significantly associated with 90-day mortality (hazard ratio [HR], 1.610; 95% confidence interval [CI], 1.095-2.365; p = 0.015) and 180-day mortality (HR, 1.549; 95% CI, 1.057-2.271; p = 0.025). Notably, the association remained consistent following PSM and IPTW.
Conclusions: NA withdrawal is an independent risk factor for death in patients with HBV-ACLF, underlining the importance of adherence to NA therapy in patients with chronic hepatitis B.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.70213 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of artificial liver plasma perfusion combined with plasma exchange therapy on clinical efficacy and short-term prognosis of hepatitis B virus-related acute-on-chronic liver failure with or without HIV infection.
BMC Infect Dis
August 2025
Department and Institute of Good Clinical Practice, Public Health Clinical Center of Chengdu, 377, JingMing Avenue, Chengdu, 610000, SiChuan Province, China.
Objective: To compare the effectiveness of plasma perfusion combined with plasma exchange (PP + PE) artificial liver support system in patients with hepatitis B virus-associated acute-on-chronic liver failure with and without HIV infection (HBV-ACLF/HIV(+) and HBV-ACLF/HIV(-), respectively) and to assess the clinical value and safety of the artificial liver support system.
Methods: This study involved 162 patients diagnosed with HBV-ACLF and hospitalized at Chengdu Public Health Clinical Medical Center from January 2020 to January 2025, in accordance with the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Acute-on-Chronic Liver Failure (2025 edition). Seventeen patients with tumors, severe underlying diseases, or other hepatitis virus infections were excluded.
Predicting prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure from longitudinal ultrasound images using a multi-task deep learning approach.
Ann Med
December 2025
Department of Ultrasound, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Background: Individualized risk stratification in hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) remains challenging. This study aimed to develop and validate a multi-task deep learning model using longitudinal liver ultrasound images for prognosis prediction.
Methods: A total of 372 HBV-ACLF patients were retrospectively enrolled, and baseline (T0) and 5 days post-admission (T1) liver ultrasound images, clinical data, and 30-day outcome (survival/mortality) were collected.
Single-cell multimodal analysis reveals the dynamic immunopathogenesis of HBV-ACLF progression.
Gut
August 2025
State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, National Medical Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhej
Background: Acute-on-chronic liver failure (ACLF) is a life-threatening syndrome involving dysfunction of multiple immune cell types.
Objective: This study aimed to comprehensively depict the dynamic trajectory of immune responses throughout the disease course of HBV-related ACLF (HBV-ACLF).
Design: Single-cell RNA sequencing and single-cell proteomics were performed on the peripheral blood mononuclear cells of 45 samples from 17 patients who were hospitalised (progressive/stable/recovering course of HBV-ACLF, 6/5/6) and 15 control subjects (liver cirrhosis, chronic hepatitis B and healthy controls, 5/5/5).
Circulating Cell-Free Mitochondrial DNA as a Prognostic Biomarker in Patients With HBV-Related Acute-on-Chronic Liver Failure.
J Med Virol
August 2025
Department of Liver Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Acute-on-chronic liver failure (ACLF), particularly hepatitis B virus-related ACLF (HBV-ACLF), is a severe condition with high short-term mortality. This study aimed to evaluate the prognostic value of circulating cell-free mitochondrial DNA (cf-mtDNA) in predicting short-term mortality in HBV-ACLF patients. A total of 320 HBV-ACLF patients were included in the study population, with 192 patients in the derivation cohort and 128 in the validation cohort.
View Article and Find Full Text PDFRoles of inflammatory cytokines in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure and CAR-T therapy.
Virol J
August 2025
Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
Objective: To investigate the association between inflammatory cytokines and liver function indices in hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) patients and chimeric antigen receptor (CAR) T therapy recipients, with the aim of identifying prognostic biomarkers and elucidating the pathophysiological roles of inflammatory cytokines in HBV-ACLF.
Methods: This retrospective cohort study analyzed clinical data from three groups: 68 patients with confirmed HBV-ACLF, 30 patients with pre-HBV-ACLF, and 372 hematologic malignancy patients receiving CAR-T therapy with preserved liver function at the First Affiliated Hospital of Soochow University.
Results: Serum interleukin (IL)-10 levels demonstrated a progressive increase across the groups [healthy controls: 0.